

**National Heart
Lung and Blood Institute**
People Science Health

**NHLBI Mid-Atlantic
Innovation Conference
October 15, 2012**

Gilchrist Hall Auditorium
Johns Hopkins University
9601 Medical Center Drive
Rockville, MD 20850

PRE SCIENCE
INTERNATIONAL



BioHealth InnovationSM
Maryland's Commercialization Collaborative

MONTGOMERY
ECONOMIC DEVELOPMENT
MONTGOMERY COUNTY, MARYLAND
Locate. Innovate. Accelerate.

Maryland **TEDCO**
Technology-Development-Corporation



 **JOHNS HOPKINS**
UNIVERSITY
MONTGOMERY COUNTY

OTT



MARYLAND
BIOTECHNOLOGY
CENTER

Agenda

9:00-10:00 NHLBI Speaker Bios

8:30 - 9:00 a.m.

Registration & Light
Breakfast

9:00 - 10:00 a.m.

NHLBI Panel

10:00 - 10:45 a.m.

Investor Perspectives:

NEA

Noble BioVentures

MD Bio Center

Medimmune

10:45 - 11:00 a.m.

Coffee Break

11:00 - 12:00 p.m.

Company Showcase

12:00 - 1:00 p.m.

Lunch



Jodi Black, PhD Deputy Director, Division of Extramural Research Activities

Dr. Black was appointed as the Deputy Director of the Division of Extramural Research Activities, National Heart Lung and Blood Institute in 2009. As Deputy Director, she works with the Director DERA to provide scientific and management leadership and oversight of the NHLBI extramural research and training programs.



Kurt Marek, PhD Program Director and SBIR Coordinator

Dr. Marek is a Program Director at the National Heart, Lung, and Blood Institute (NHLBI) where he coordinates the Small Business Innovation Research (SBIR) program. In this role, he develops, manages, and evaluates scientific programs to support small businesses performing research and development on innovative biomedical products. Dr. Marek provides advice to small businesses on all aspects of the SBIR program, including funding opportunities, the application process, and commercializing technologies.



Traci Mondoro, PhD Health Scientist Administrator, Division of Blood Diseases and Resources

Traci Mondoro received her Ph.D. in biochemistry from the University of Tennessee at Memphis. Dr. Mondoro joined NHLBI in 2001 as a health scientist administrator in the Division of Blood Diseases and Resources. She manages two large NHLBI programs: the Transfusion Medicine/Hemostasis Clinical Trial Network (TMH CTN) and the Production Assistance for Cellular Therapies (PACT) program.



Sonia Skarlatos, PhD Deputy Director, Division of Cardiovascular Sciences

Dr. Sonia Skarlatos is Deputy Director of the Division of Cardiovascular Sciences at the National Heart, Lung, and Blood Institute (NHLBI), and the NHLBI Gene Therapy Coordinator. She received her Ph.D. in Physiology from Pennsylvania State University. In her present position, she is responsible for the overall planning, development and implementation of national and international innovative research activities pertaining to heart and vascular diseases as well as participating in the development of policies and procedures related to the everyday management of the Division of Cardiovascular Sciences.



Gail Weinmann, MD Deputy Director, Division of Lung Diseases

Gail G. Weinmann, MD, is Deputy Director of the Division of Lung Diseases at the National Heart, Lung, and Blood Institutes (NHLBI) of the National Institutes of Health (NIH), which is responsible for fostering and supporting research on the lungs in health and disease. Dr. Weinmann came to the NHLBI from the Johns Hopkins University where she was an Associate Professor in the School of Public Health's Department of Environmental Health Sciences with a joint appointment in the School of Medicine's Department of Medicine. Dr. Weinmann received her AB degree from Barnard College and her MD degree from Weill Cornell Medical College.

10:00-10:45 Investor Speaker Bios



Judith Britz, PhD Executive Director, Maryland Biotechnology Center

Dr. Judy Britz, the Executive Director of the Maryland Biotechnology Center has more than 25 years of experience in the *in vitro* diagnostics industry. She is a serial entrepreneur who served as the President and CEO of Cylex Inc. and the General Manager of Sienna Biotech, Inc., both companies which successfully introduced a series of patented diagnostic products, navigating them through the FDA in record time, manufacturing kits under GMP and marketing them to hospitals in the US, Europe, and Asia.



Kenneth Carter, PhD Partner, Noble BioVentures

Dr. Kenneth Carter has been involved in the formation and early stage development of several biotechnology companies as a co-founder, consultant or member of the board of directors. He also served recently as a special advisor to the Maryland Governor's Life Sciences Advisory Board and is on the Advisory Council for the Center for Biotechnology Education at Johns Hopkins University where he also holds an adjunct faculty appointment.




Sara Nayeem, MD Principal, NEA

Dr. Sara Nayeem focuses on investments in biopharmaceutical companies at New Enterprise Associates (NEA). She has also been involved in NEA's investments in 3-V Biosciences and Prosensa and assists with the management of several of NEA's publicly traded portfolio companies. Prior to joining NEA, Sara was an Associate with Merrill Lynch's Global Healthcare Group and worked as an Investment Banking Analyst at Morgan Stanley.



John Trainer Executive Director BD, MedImmune

John Trainer is the head of the Business Development team at MedImmune (the global biologics arm of Astra-Zeneca) for Oncology, Infection, Neuroscience, Autoimmunity / Inflammation, Respiratory, Technology and New Opportunities therapeutic areas. His focus is on all stages of development, from early-stage research deals to commercial collaborations. Before joining the Business Development team, John led the Infection team in Global Strategic Marketing, working closely with the R&D leadership to set the strategic priorities and actions for this portfolio. John also worked on the Synagis commercial team, focusing on physician interactions and advocacy outreach. Before MedImmune, John worked at the strategy consulting firm Monitor Group in Boston and Washington, DC. John has an MBA from Harvard Business School and a BA from Harvard College.



Richard A. Bendis President & CEO, BioHealth Innovation, Inc.

Mr. Richard Bendis currently serves as both the President and CEO of BioHealth Innovation, Inc. (BHI) and as the founding President and CEO of Innovation America (IA). As one of the most recognized experts in the field of innovation economy, Mr. Bendis has served on numerous distinguished boards and task forces including the White House U.S. Innovation Partnership Advisory Task Force, the Small Business Innovation Research Committee, the National Association of State Venture Funds board; State Science and Technology Institute, and the Ernst and Young Entrepreneurial Institute as a national/regional judge.

11:00-12:00 Company Showcase



GPB Scientific, LLC has developed a disruptive technology that achieves cell separation more efficiently and economically than any other method currently in use. Cells in peripheral blood contain vital clinical information required to assess human health, detect disease, and monitor therapy. GPB's products enable the separation, enrichment, isolation and capture of cells in blood with unprecedented cell yield, viability and purity. The company's technology addresses major unmet needs in research, diagnostics, therapeutics and disease management.



HemoShear is a biotechnology research company that works in strategic collaborations with pharmaceutical and biotechnology companies to develop safer and more effective therapies.



HemoSonics is a medical device company founded to develop and bring to market innovative diagnostics to assess and guide the rapid treatment of bleeding and clotting disorders. HemoSonics' mission is to save lives and improve quality of life while reducing costs through the use of its products in all applicable clinical settings. The company's first product is an in vitro diagnostic device using a consumable test cartridge. Follow on products will extend its reach into the central lab and primary care markets.



New Health Sciences, Inc. acquired control of the Hemanext technology in 2006 and has since led the development of this innovative blood storage system. Hemanext is a novel technology to deliver red blood cells of higher efficacy for transfusion therapy and, at the same time, extend the shelf life of refrigerated red blood cells. NHSi has licensed the HASP technology from Boston University and Los Alamos National Laboratory. NHSi has funded development of the Hemanext technology through a combination of two NIH SBIR grants and private financing.



PocketSonics, Inc. was formed in January 2004 by three University of Virginia professors to commercialize technology developed in their laboratories. Development was driven by the clinical need to improve portable ultrasound visualization for vascular access guidance. Bringing together a combination of academic and commercial expertise in Integrated Circuit Design Electronics, Acoustics & Transducer Design, and Novel Beamforming Algorithms, the team spawned ideas that went contrary to how traditional ultrasound technologies had ever been engineered before.

Notes:

12:00-1:00 Poster Company Profiles



Bioengineering Consultants is a small engineering research and development company serving medical professionals and medical device companies for the design and development of specialized instruments and products. Its expertise has been primarily in the orthopedic field but more recently has diversified to other medical areas (gastroenterology, pulmonary, urology and gynecology) with the collaboration of other university faculty.



CW Optics, Inc. is a small technology company specializing in biophotonic devices for human physiological monitoring. The company's R&D work has been funded mainly through competitive SBIR grants from NIH, including two Phase IIBs.




Engineering and Scientific Research Associates, is a small business entity incorporated in the State of Maryland. ESRA is interested in research & development, evaluation, and testing of medical devices. Currently ESRA is working on an innovative respiratory diagnostic device called the "Airflow Perturbation Device (APD)". APD is a simple, inexpensive, portable, and noninvasive respiratory diagnostic device. ESRA is supported by 4 NIH-SBIR Grants; 3 Phase I and one Phase II.



IGI Technologies is a Maryland-based Medical imaging technology startup. The company was founded in 2007 by Raj Shekhar, PhD and William Plishker, PhD as a vehicle to commercialize years of academic research. The company was the winner of 2007 University of Maryland Business plan competition. With Over 2 Million dollars raised through 3 small-business technology transfer grants from the National Institutes of Health, the company is transforming university-based research of advanced and accelerated medical image processing into world class products.



Quality Biological (QBI), a Maryland based bio-manufacturer of high quality reagents, buffers, and media, provides products and outsource support to federal government agencies, academic research groups, as well as life science and pharmaceutical companies. QBI provides products and supplies for the molecular biology – such as buffers, and RNA and DNA reagents – and for the cell biology laboratory – including traditional cell culture media, the QBSF® range of serum-free media, and products for stem cell culture and hematopoiesis. QBI has placed an increasing emphasis on research that it hopes will provide not only answers to important questions in the area of hematopoiesis, but also products that will make the work of researchers in that and other disciplines more productive.



Weinberg Medical Physics, LLC. seeks to exploit the imaging and interventional benefits of proprietary ultra-fast magnetic gradient technology, achieving (without side effects) a ten-fold increase over the magnetic fields previously reached. Potential applications include *in vivo* microscopy, which is improved coronary artery imaging.

Host and Partners



www.nhlbi.nih.gov

The National Heart, Lung, and Blood Institute

The NHLBI provides global leadership for research, training, and education to promote the prevention and treatment of heart, lung, blood, and sleep diseases and disorders and to enhance the health of all individuals so that they can live longer and more fulfilling lives. The NHLBI is the third largest research organization at the National Institutes of Health (NIH), and has a 2012 budget of more than \$3 billion. The NHLBI provides grant and contract funding opportunities to support small businesses performing research and development on technologies related to its mission.



www.biohealthinnovation.org

BioHealth Innovation, Inc.

BioHealth Innovation, Inc. (BHI) is an innovation intermediary that translates market-relevant research into commercial success by connecting management, funding, and markets. BHI's vision is to transform the Central Maryland region into a leading global bio-health entrepreneurial and commercialization hub.

PRESCIENCE INTERNATIONAL

www.prescienceintl.com

Prescience International

Prescience is dedicated to the global adoption of life science, cleantech and other high-growth technologies which generate sustainable economic results and have a positive social impact. Prescience engages with private and public clients to create and operate unique innovation centers, design and deliver world-class educational programs, and provide targeted commercialization support services.



MARYLAND
BIOTECHNOLOGY
CENTER